当前位置: X-MOL 学术Annu. Rev. Med. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Circulating Tumor DNA: Measurement and Clinical Utility
Annual Review of Medicine ( IF 15.1 ) Pub Date : 2018-01-29 00:00:00 , DOI: 10.1146/annurev-med-041316-085721
Joshua Donaldson 1 , Ben Ho Park 1, 2
Affiliation  

Circulating tumor DNA (ctDNA) is a component of the “naked” DNA found in blood. It can be isolated from plasma and represents combined genetic material from the primary tumor and metastases. Quantitative and qualitative information about a cancer, including mutations, can be derived using digital polymerase chain reaction and other technologies. This “liquid biopsy” is quicker and more easily repeated than tissue biopsy, yields real-time information about the cancer, and may suggest therapeutic options. All stages of cancer therapy have the ability to benefit from ctDNA, starting with screening for cancer before it is clinically apparent. During treatment of metastatic disease, it is useful to predict response and monitor disease progression. Currently, ctDNA is used in the clinic to select patients who may benefit from epidermal growth factor receptor–targeted therapy in non–small cell lung cancer. In the future, ctDNA technology promises useful applications in every part of clinical oncology care.

中文翻译:


循环肿瘤DNA:测量和临床实用性

循环肿瘤DNA(ctDNA)是血液中发现的“裸露” DNA的组成部分。它可以从血浆中分离出来,代表原发肿瘤和转移灶的组合遗传物质。可以使用数字聚合酶链反应和其他技术来获得有关癌症的定量和定性信息,包括突变。这种“液体活检”比组织活检更快速,更容易重复,可产生有关癌症的实时信息,并可能提供治疗选择。癌症治疗的所有阶段均具有从ctDNA获益的能力,从在临床上尚无明显的癌症筛查开始。在转移性疾病的治疗过程中,预测反应和监测疾病进展非常有用。目前,ctDNA在临床中用于选择在非小细胞肺癌中可能受益于表皮生长因子受体靶向治疗的患者。将来,ctDNA技术有望在临床肿瘤学护理的各个部分得到有用的应用。

更新日期:2018-01-29
down
wechat
bug